Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 19/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 17/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 17/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2976073 | 0.87 | ADORA3 (0.51) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL2989916 | 0.86 | ADORA2A (0.52) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL2976119 | 0.85 | ADORA3 (0.50) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL2991238 | 0.84 | ADORA2A (0.55) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL2985921 | 0.84 | ADORA3 (0.68) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL2991223 | 0.84 | ADORA2A (0.57) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL2989880 | 0.82 | ADORA2A (0.55) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL2991330 | 0.81 | ADORA2A (0.57) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL2989927 | 0.79 | ADORA2A (0.52) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL2980224 | 0.79 | ADORA2A (0.52) | ADORA2AADORA1ADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173914-A1 | PHARMACEUTICALS, COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. | 2010-07-08 | — | — | US | claimed |
| EP-2117313-A1 | PHARMACEUTICALS, COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA Inc. (US) | 2009-11-18 | — | — | EP | claimed |
| WO-2008088927-A1 | PHARMACEUTICALS, COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2008-07-24 | — | — | WO | claimed |
| US-20100173914-A1 | PHARMACEUTICALS, COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. | 2010-07-08 | — | — | US | disclosed |
| US-20100173914-A1 | PHARMACEUTICALS, COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. | 2010-07-08 | — | — | US | disclosed |
| EP-2117313-A1 | PHARMACEUTICALS, COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008088927-A1 | PHARMACEUTICALS, COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173914-A1 | PHARMACEUTICALS, COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | ADORA2A, P2RY1, P2RY6 | ADORA2A 1/4885ADORA1 8/4885ADORA3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.